Current cancer drug discovery method flawed, study suggests

The primary method used to test compounds for anti-cancer activity in cells is flawed, researchers report. The findings cast doubt on methods used by the entire scientific enterprise and pharmaceutical industry to discover new cancer drugs.The researchers have developed a new metric to evaluate a compound’s effect on cell proliferation — called the DIP (drug-induced proliferation) rate — that overcomes the flawed bias in the traditional method.